FIVEPRIME AND BOEHRINGER INGELHEIM INITIATE RHEUMATOID ARTHRITIS COLLABORATION

Five Prime Therapeutics, Inc. announced today to have entered into a two year collaborative research and license agreement with Boehringer Ingelheim to discover novel therapeutic products to treat rheumatoid arthritis and other diseases. In a multi product deal potentially worth over $75 million, FivePrime will receive an upfront fee and research support, and Boehringer Ingelheim has exclusive worldwide rights to develop and commercialize products and targets discovered in exchange for future milestones and royalties. Further details of the agreement have not been disclosed.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060425005668&newsLang=en)